Introduction: Accumulating evidence has implicated a pivotal role for FOXO3, FOXM1 and SIRT6 in cancer progression. The majority of researches focused on the functions of these proteins in drug resistance, but their relationships with radiotherapy (RT) response remain unclear. In this study, we examined protein expression of FOXO3, FOXM1 and SIRT6 and their clinical significance in a Swedish rectal cancer trial of preoperative RT.
Methods: Expression of FOXO3, FOXM1 and SIRT6 protein was examined by immunohistochemistry in patient samples. Genetic analysis of FOXO3, FOXM1 and SIRT6 were performed by cBioportal and MEXPRESS database. Gene-gene network analysis was conducted using GeneMANIA. Functional enrichment analysis was performed based on LinkedOmics and Metascape online software.
Results: FOXO3 and FOXM1were mainly expressed in the cytoplasm in both normal and tumour tissues, and SIRT6 in both the cytoplasm and nucleus in normal and tumour tissues. FOXO3 and FOXM1 expression increased from normal mucosa to primary cancer (P < 0.001), while SIRT6 expression decreased from normal mucosa to primary cancer (P < 0.001). High FOXO3 expression correlated with late TNM stage (P = 0.040), distant metastasis (P = 0.032) and independently with disease free survival (DFS) in the RT patients (HR = 7.948; P = 0.049; 95% CI = 1.002-63.032) but not in non-RT patients (P > 0.05). Genetic analysis indicated that DNA methylation status contributed to FOXO3 overexpression. Functional enrichment analysis demonstrated that FOXO3 was closely related to metabolism-related signalling pathway which in turn associated with cancer radioresistance. Moreover, there were strong gene-gene interactions between FOXO3 and metabolism-related signalling.
Conclusions: Our findings suggest that FOXO3 may be a prognostic factor in rectal cancer patients with RT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149220 | PMC |
| http://dx.doi.org/10.1016/j.heliyon.2023.e15342 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Effects of Peiminine on biological behavior and chemotherapy resistance of ovarian cancer by regulating the FOXO3-FOXM1 signaling axis].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
November 2024
Department of Gynecology, Qinghai Red Cross Hospital, Xining 810000, China. *Corresponding author, E-mail:
Objective To investigate the effects of Peiminine (PMI) on the proliferation, invasion, migration, apoptosis, and chemotherapy resistance of ovarian cancer by regulating the forkhead box protein O3 (FOXO3)-forkhead box transcription factor M1 (FOXM1) signaling axis. Methods Ovarian cancer cells SKOV3 and SKOV3/cisplatin (DDP) were used as research objects. The proliferation inhibition of DDP on SKOV3 and SKOV3/DDP cells and the proliferation inhibition of of PMI on SKOV3/DDP cells were detected by MTT method.
View Article and Find Full Text PDFSPIN1 accelerates tumorigenesis and confers radioresistance in non-small cell lung cancer by orchestrating the FOXO3a/FOXM1 axis.
Cell Death Dis
November 2024
Department of Oncology, the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi province, PR China.
Despite the importance of radiation therapy as a nonsurgical treatment for non-small cell lung cancer (NSCLC), radiation resistance has always been a concern because of poor patient response and outcomes. Therefore, it is crucial to identify novel targets to increase the effectiveness of radiotherapy and investigate the mechanisms underlying radioresistance. Previously, we demonstrated that Spindlin 1 (SPIN1) was related to tumour initiation and progression.
View Article and Find Full Text PDFCepharanthine sensitizes gastric cancer cells to chemotherapy by targeting TRIB3-FOXO3-FOXM1 axis to inhibit autophagy.
Phytomedicine
December 2024
The Affiliated Hospital of Qingdao University, Department of Oncology, No.16 Jiangsu Road, Shinan District, Qingdao 266000, China. Electronic address:
Background: Gastric cancer is among the common solid tumors. Chemotherapy resistance is the most common issue in gastric cancer treatment. Inhibiting intracellular autophagy may be a feasible method for overcoming chemotherapy resistance.
View Article and Find Full Text PDFIntegrating bioinformatics and experimental models to investigate the mechanism of the chelidonine-induced mitotic catastrophe via the AKT/FOXO3/FOXM1 axis in breast cancer cells.
Biomol Biomed
May 2024
Pharmaceutical Engineering Technology Research Center, Harbin University of Commerce, Harbin, China.
Breast cancer (BC) is currently the most frequent and lethal cancer among women, and therefore, identification of novel biomarkers and potential anticancer agents for BC is crucial. Chelidonine is one of the main active ingredients of Chelidonium majus, which has been applied in Chinese medicine prescriptions to treat cancer. This paper aimed to evaluate the ability of chelidonine to trigger mitotic catastrophe in BC cells and to clarify its mechanism through the AKT/FOXO3/FOXM1 pathway.
View Article and Find Full Text PDFThe Role of Polo-Like Kinase 1 in Regulating the Forkhead Box Family Transcription Factors.
Cells
May 2023
Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, VA 23298, USA.
Polo-like kinase 1 (PLK1) is a serine/threonine kinase with more than 600 phosphorylation substrates through which it regulates many biological processes, including mitosis, apoptosis, metabolism, RNA processing, vesicle transport, and G DNA-damage checkpoint recovery, among others. Among the many PLK1 targets are members of the FOX family of transcription factors (FOX TFs), including FOXM1, FOXO1, FOXO3, and FOXK1. FOXM1 and FOXK1 have critical oncogenic roles in cancer through their antagonism of apoptotic signals and their promotion of cell proliferation, metastasis, angiogenesis, and therapeutic resistance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!